Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Researchers mapped the safe dosing window for venetoclax after stem cell transplant, helping physicians balance benefit and harm.
This study defines the optimal timing, dosing, and safety boundaries for venetoclax as post-allogeneic stem cell transplant maintenance therapy in high-risk AML and MDS. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- cohort_study
- Category
- Other
- Maturity
- Validated
- Journal
- Hematol Oncol
Why it surfaced
Post-transplant relapse in AML/MDS carries near-universal poor prognosis; defining a therapeutic window for venetoclax maintenance fills a critical evidence gap for a widely used agent; novelty is high as this specific application lacks dedicated phase 3 evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.